Human Growth Hormone

Phase 3Small molecule

AAscendis Pharma A/S

Human Growth Hormone is one of 69 small molecule programs targeting Short stature. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Short StatureActive, not recruiting

Growth Hormone DeficiencyActive, not recruiting

GrowthActive, not recruiting

Short StaturePhase 2

Active, not recruiting

Growth Hormone DeficiencyPhase 3

Active, not recruiting

GrowthPreclinical

Active, not recruiting

Competition

Competitive Landscape

364 competitors in Growth

#DrugCompanyPhaseTrials

Human Growth Hormone

AAscendis Pharma A/S

Phase 3

3 2

Lovenox

Sanofi

Preclinical

2 3

Lenvima

Eisai

Preclinical

1 4

Herceptin

OOrganon and Co

Preclinical

4 5

Somavaratan

EGRIFTA WR

2 7

Neupogen

EEastern Cooperative Oncology Group

Preclinical

1 8

Prilosec

DDexcel Pharma Technologies Ltd.

Preclinical

1 9

Accutane

CConrado Roberto Hoffmann Filho

Preclinical

1 10

Alli

EEngelhard Arzneimittel GmbH & Co.KG

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2036

Phase 2Recruiting

Short Stature

NCT06382155

Clinical

Trials by Indication[1]

Growth3 trials

Human Growth Hormone Pre-treatment for 6 Weeks Prior to Ovulation Induction for IVF

Unknown status·CCenter for Human Reproduction·Phase 1/2·NCT02179255·30 enrolled

A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients.

Completed·RRoyal Marsden NHS Foundation Trust·Phase 2/3·NCT00300664·150 enrolled

Growth Hormone Signaling in Vivo in Humans

Completed·UUniversity of Aarhus·N/A·NCT00512473·8 enrolled

Growth Hormone Deficiency2 trials

Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults With Growth Hormone Deficiency

Completed·SStanford University·Phase 3·NCT01007071·11 enrolled

A Multicenter, Phase 2, Randomized, Open Label, Active-controlled, Parallel-group Study Investigating the Safety, Tolerability, and Efficacy of Different Dose Levels of ACP-001 Administered Once Weekly Versus Standard Daily rhGH Replacement Therapy in Pre-pubertal Children With Growth Hormone Deficiency (GHD)

Completed·AAscendis Pharma A/S·Phase 2·NCT01947907·53 enrolled

Treatment1 trial

Treatment of GHD Associated With CHF

Unknown status·FFederico II University·Phase 3·NCT03775993·64 enrolled

Tics1 trial

Pharmacokinetics and Pharmacodynamics of ACP-001 (TransCon PEG hGH)

Completed·AAscendis Pharma A/S·Phase 1·NCT01010425·44 enrolled

Dexamethasone1 trial

Dexamethasone/Pancreatic Clamp P&F

Withdrawn·—·Phase 1·NCT06126354

1 more indication

Short stature1 trial

A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature

Recruiting· BioMarin Pharmaceutical logo

BioMarin Pharmaceutical·Phase 2·NCT06382155·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Human Growth Hormone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Human Growth Hormone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Human Growth Hormone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ascendis Pharma A/S company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAscendis Pharma A/S

Human Growth Hormone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2036

Trials by Indication[1]

Growth3 trials

Growth Hormone Deficiency2 trials

Treatment1 trial

Tics1 trial

Dexamethasone1 trial

Short stature1 trial

References

Drug Info

Quick Facts

Related News